Historical Information

Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a clinical stage development company with a cell therapy pipeline focused on immune modulation and select cardiovascular indications, announces today that the Company’s leadership will participate at the following upcoming

Conference Call scheduled for today at 5:00 p.m. Eastern time BASKING RIDGE, N.J. (May 18, 2017)  – Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a clinical stage development company with a cell therapy pipeline focused on immune modulation and select cardiovascular

Conference call scheduled for May 18, 2017 at 5:00 p.m. Eastern time BASKING RIDGE, N.J., (May 15, 2017) – Caladrius Biosciences, Inc. (NASDAQ: CLBS)  (“Caladrius” or the “Company”), a cell therapy company with a therapeutic development pipeline focused on immune modulation and select

BASKING RIDGE, N.J., (May 9, 2017) – Caladrius Biosciences, Inc. (NASDAQ: CLBS)  (“Caladrius” or the “Company”), a cell therapy company with a therapeutic development pipeline focused on immune modulation and select cardiovascular conditions as well as a subsidiary, PCT, a development and

BASKING RIDGE, N.J., May 1, 2017  — Caladrius Biosciences, Inc. (NASDAQ: CLBS ) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline focused on immune modulation, announces today that experts from the Company’s PCT subsidiary will participate at the

BASKING RIDGE, N.J., Apr. 10, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline focused on immune modulation, announces today that the Company’s 2017 annual stockholder meeting will be held on

BASKING RIDGE, N.J., Apr. 5, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline focused on immune modulation announces today that the Company’s leadership and experts will participate at the

BASKING RIDGE, N.J., March 30, 2017 — Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company advancing a select therapeutic development pipeline, announces today that four additional clinical sites, including Joslin Diabetes Center, an affiliate of Harvard

Annual revenue growth of 57% exceeds 2016 financial guidance Conference call begins today at 8:30 am Eastern time BASKING RIDGE, N.J., (March 17, 2017) – Caladrius Biosciences, Inc. (NASDAQ: CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline

Caladrius expected to emerge as a well-capitalized cell therapeutics-only development company with multiple proprietary technology platforms Conference call begins tomorrow, March 17, 2017 at 8:30 am Eastern time BASKING RIDGE, N.J., (March 16, 2017) – Caladrius Biosciences, Inc.